Description: Opthea Limited operates as a biotechnology company. The Company develops therapies for diabetic macular edema, corneal neovascularization and transplantation, and dry eye disease. Opthea serves patients and healthcare providers in Australia.
Home Page: opthea.com
OPT Technical Analysis
650 Chapel Street
South Yarra,
VIC
3141
Australia
Phone:
61 3 9826 0399
Officers
| Name | Title |
|---|---|
| Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | MD, CEO & Exec. Director |
| Ms. Judith J. Robertson B.A., M.B.A. | Chief Commercial Officer |
| Dr. Joel Naor M.D., MBA, MSc | Chief Medical Officer |
| Ms. Karen Adams CPA | VP of Fin. & Company Sec. |
| Mr. Timothy E. Morris CPA, CPA | Chief Financial Officer |
| Ms. Annie Lee | Fin. & Operations Mang. |
| Dr. Michael Gerometta Ph.D. | Head of Chemistry, Manufacturing & Controls Devel. |
| Mr. Bruno Gagnon BPHARM, M.Sc. | Sr. VP of Global Clinical Operations |
| Dr. Ian Leitch | Director of Clinical Research |
| Dr. James Goding | Independent Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 6.734 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.4761 |
| Price-to-Sales TTM: | 1313.1346 |
| IPO Date: | 2012-04-12 |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |